The Patent Finder

Ligand Pharmaceuticals Incorporated

Also on record
Records under this name other than the patents Ligand Pharmaceuticals Incorporated holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 85 patents it holds.

Back to Ligand Pharmaceuticals Incorporated

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,241,650Device, Method, and Use for Treatment of Neuropathy Involving Nitric Oxide
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,427,605Cosmetic Treatment with Nitric Oxide, Device for Performing Said Treatment and Manufacturing Method Therefor
Formerly held
In force
 · High confidence
In forceHigh confidence
US 7,314,887Thrombopoietin activity modulating compounds and methods
Term ended
Term ended Oct 21, 2025 · USPTO record
Term endedTerm ended Oct 21, 2025USPTO record
US 8,865,918Androgen receptor modulator compounds and methods
Term ended
Ended no later than Mar 11, 2025 · USPTO record
Term endedEnded no later than Mar 11, 2025USPTO record
US 9,359,285Androgen receptor modulator compounds and methods
Term ended
Ended no later than Mar 11, 2025 · USPTO record
Term endedEnded no later than Mar 11, 2025USPTO record
US 7,071,2055-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
Term ended
Term ended Oct 10, 2023 · USPTO record
Term endedTerm ended Oct 10, 2023USPTO record
US 7,084,1515-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds
Term ended
Term ended Oct 10, 2023 · USPTO record
Term endedTerm ended Oct 10, 2023USPTO record
US 9,144,557Hematopoietic growth factor mimetic small molecule compounds and their uses
Lapsed on the fee record
Ended Sep 29, 2023 · USPTO record
Lapsed on the fee recordEnded Sep 29, 2023USPTO record
US 7,214,690Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
Term ended
Term ended Aug 7, 2023 · USPTO record
Term endedTerm ended Aug 7, 2023USPTO record
US 6,992,108Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
Formerly held
Term ended
Term ended Jan 31, 2023 · USPTO record
Term endedTerm ended Jan 31, 2023USPTO record
10 of 160 patents shown.
Pro members see all 160.
Pro members: see all 160 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited